GeoVax Labs, Inc. (Nasdaq: GOVX) today reported financial results for the second quarter ended June 30, 2026, and provided a business update highlighting continued progress toward initiating a pivotal immunobridging study for its GEO-MVA vaccine candidate under an expedited regulatory pathway. The company also advanced its Gedeptin immuno-oncology program.
During the quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study, which was established through formal Scientific Advice discussions with the European Medicines Agency (EMA). Activities included clinical study readiness, manufacturing preparedness, and engagement with government and public health stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GeoVax believes GEO-MVA is uniquely positioned to help address the growing need for diversified global MVA vaccine manufacturing capacity. The company continued utilization of previously manufactured and released cGMP clinical trial material and advanced the AGE1 continuous cell-line manufacturing platform for future commercial-scale production.
In its immuno-oncology program, GeoVax continues advancing Gedeptin, an investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies by improving responsiveness in immunologically resistant tumors.
GeoVax reported a net loss of $4.4 million for the three-month period ended June 30, 2026, compared to $5.4 million for the same period in 2025. Research and development expenses decreased to $3.1 million from $4.7 million, primarily due to lower costs associated with the discontinued BARDA contract and reduced spending on GEO-CM04S1 clinical activities. General and administrative expenses decreased to $1.3 million from $1.5 million, reflecting lower investor relations consulting costs and reduced stock-based compensation.
The company reported cash balances of approximately $3.1 million as of June 30, 2026. GeoVax continues to prioritize resources toward programs offering the strongest combination of clinical differentiation, regulatory clarity, and commercial opportunity, including execution of the GEO-MVA pivotal immunobridging clinical program, advancement of scalable manufacturing capabilities, and engagement supporting future government procurement opportunities.
